Caricamento...
Therapeutic Sequencing in ALK(+) NSCLC
Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK(+) NSCLC) is a model disease for the use of targeted pharmaceuticals in thoracic oncology. Due to higher systemic and intracranial efficacy, the second-generation ALK tyrosine kinase inhibitors (TKI) alectinib and brigatinib have...
Salvato in:
| Pubblicato in: | Pharmaceuticals (Basel) |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7912146/ https://ncbi.nlm.nih.gov/pubmed/33494549 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14020080 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|